the aid library

LIST OPTIONS

Filter

1826

Download (226)

View PDF (199)

Guidelines for the Medicines and Therapeutics Committee (MTCs) 04

Ministry of Health, Zambia (2017) C1

Download (410)

View PDF (486)

National Policy for the Establishment and Functioning of Pharmaceutical and Therapeutics Committees in South Africa

Department of Health, Republic of South Africa (2015) C2

Download (119)

View PDF (161)

Control and surveillance of human African trypanosomiasis: report of a WHO Expert Committee

World Health Organization WHO (2013) C_WHO

The previous report of the WHO Expert Committee on this disease followed a meeting in 1995. Intensive, coordinated efforts against HAT during the intervening 18 years have resulted in a decrease in incidence to a point at which elimination is considered feasible. This report provides informati... more

Download (451)

View PDF (1080)

The Wise List 2015

Stockholm Drug and Therapeutics Committee (2015) C_WHO

with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden

Download (296)

View PDF (461)

Executive summary: the selection and use of essential medicines 2021

World Health Organization WHO (2021) C_WHO

Report of the 23rd WHO Expert Committee on the selection and use of essential medicines This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)... more

Download (1919)

View PDF (1347)

Selection and Use of Essential Medicines 2021
recommended

World Health Organization WHO (2021) C_WHO

The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo... more

Download (38281)

View PDF (2331)

Emergency Drug Guidelines. Fiji

Ministry of Health, Fiji World Health Organization WHO (2008) C_WHO

The publication of the Second Edition of the Emergency Drug Guidelines represents the culmination of the efforts of the National Drugs and Therapeutics Committee (NDTC) to publish clinical drug guidelines for common diseases seen in Fiji. These guidelines are targeted for health care professionals w... more

Download (165)

View PDF (147)

WHO advisory committee on variola virus research: report of the twenty-third meeting, virtual meeting, 3-4 November 2021

World Health Organization (WHO) (2021) C_WHO

The Committee discussed the implications for preparedness for smallpox-like events reflected by the ongoing COVID-19 pandemic. The Committee noted how quickly diagnostics and vaccines could be developed and deployed when resources and political will were abundant. This rapidity was also due to the f... more

Download (138)

View PDF (185)

Therapeutics for Ebola virus disease
recommended

World Health Organization WHO (2022) C_WHO

The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il... more

Download (227)

View PDF (269)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (420)

View PDF (600)

India: Report of the Core-Committee for Revision of National List of Essential Medicines November 2015

Ministry of Health & Family Welfare (MOHFW), Government of India (2015) C1

Download (142)

View PDF (197)

COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool: a module from the suite of health service capacity assessments

World Health Organization WHO (2021) C_WHO

Download (456)

View PDF (829)

Fourth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus

World Health Organization WHO (2016)

Download (370)

View PDF (323)

Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19
recommended

World Health Organization WHO (2021) C_WHO

Interim Guidance, 12 July 2021; This tool was developed to assess present and surge capacities for the treatment of COVID-19 in health facilities. It allows health facilities to assess the availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to ident... more

Download (107)

View PDF (172)

Belgian Antibiotic Policy Coordination Committee Policy paper for the 2014-2019 term

Erica Balligand, Michiel Costers and Evelyne Van Gastel Belgian Antibiotic Policy Coordination Committee (2014) C2

Antimicrobial resistance represents a big threat to public health. The Centers for Disease Control and Prevention (CDC) estimate that every year two million Americans are infected with a (multi-)drug resistant bacterium, resulting in 23,000 deaths. The WHO has repeatedly drawn attention to this majo... more

Selection and Use of Essential Medicines 2021 recommended

Therapeutics for Ebola virus disease recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19 recommended

Selection and Use of Essential Medicines 2021
recommended

Therapeutics for Ebola virus disease
recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19
recommended